| scholarly article | Q13442814 |
| P2093 | author name string | Carlo Chizzolini | |
| Montserrat Alvarez | |||
| Aleksandra Maria Dufour | |||
| Barbara Russo | |||
| P2860 | cites work | Controlling TGF-beta signaling | Q28139621 |
| Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship | Q28272771 | ||
| IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways | Q29614839 | ||
| Mechanisms of fibrosis: therapeutic translation for fibrotic disease | Q29620307 | ||
| The roles of Transforming growth Factor Type ?3(TGF-?3) and mast cells in the pathogenesis of scleroderma | Q33193227 | ||
| The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes | Q33470222 | ||
| Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent | Q33730117 | ||
| Specificity, diversity, and regulation in TGF-beta superfamily signaling. | Q33792305 | ||
| High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis | Q34066564 | ||
| 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative | Q34375158 | ||
| Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis | Q34452035 | ||
| IL-17 in Chronic Inflammation: From Discovery to Targeting | Q34512003 | ||
| Scleroderma | Q54165664 | ||
| Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis | Q58411438 | ||
| Scleroderma (systemic sclerosis): classification, subsets and pathogenesis | Q68330753 | ||
| Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? | Q68700570 | ||
| Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis | Q70489837 | ||
| Increased interleukin-17 production in patients with systemic sclerosis | Q73202422 | ||
| Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? | Q80842225 | ||
| Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma | Q82401401 | ||
| Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts | Q83611830 | ||
| Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms | Q84762346 | ||
| Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis | Q84909520 | ||
| Systemic sclerosis | Q89217839 | ||
| Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation | Q34527773 | ||
| Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. | Q35116144 | ||
| Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease | Q35840797 | ||
| Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients | Q36040200 | ||
| Pathogenic role of CCL2/MCP-1 in scleroderma | Q36992530 | ||
| Fibrosis in systemic sclerosis | Q37105782 | ||
| A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity | Q37402787 | ||
| Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations | Q37453883 | ||
| Interleukin-6 signaling drives fibrosis in unresolved inflammation | Q37572817 | ||
| Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. | Q37683419 | ||
| Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts | Q37691158 | ||
| Fibrosis and immune dysregulation in systemic sclerosis | Q37791685 | ||
| T cell abnormalities in systemic sclerosis with a focus on Th17 cells | Q38077615 | ||
| Transforming growth factor β--at the centre of systemic sclerosis | Q38241227 | ||
| Interleukin-6: a new therapeutic target in systemic sclerosis? | Q38288110 | ||
| IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta , NF-kappaB, and AP-1 activation | Q38297511 | ||
| Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. | Q38325637 | ||
| Interleukin 17 is a chief orchestrator of immunity | Q39314776 | ||
| Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial | Q40683161 | ||
| Is there a role for IL-17 in the pathogenesis of systemic sclerosis? | Q41997186 | ||
| Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis | Q42638573 | ||
| Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement | Q46474228 | ||
| Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon | Q46575133 | ||
| Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts | Q46892901 | ||
| Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma | Q47095125 | ||
| Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis | Q47763592 | ||
| Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. | Q47909675 | ||
| Targeting TGF-β signaling for the treatment of fibrosis. | Q49885373 | ||
| Transforming growth factor-beta regulation of IL-6 production by unstimulated and IL-1-stimulated human fibroblasts. | Q50232837 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | interleukins | Q194908 |
| P304 | page(s) | 1865 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Interleukin-6 and Type-I Collagen Production by Systemic Sclerosis Fibroblasts Are Differentially Regulated by Interleukin-17A in the Presence of Transforming Growth Factor-Beta 1 | |
| P478 | volume | 9 |
| Q64999676 | Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines. |
| Q90345176 | T-Cell Proapoptotic and Antifibrotic Activity Against Autologous Skin Fibroblasts in vitro Is Associated With IL-17A Axis Upregulation in Systemic Sclerosis |
| Q90687457 | Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer |
Search more.